Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 5 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Stephen Padilla, 4 days ago
Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).

Improving survival with CDK4/6 inhibitors in postmenopausal HR+/HER2-metastatic breast cancer patients

Rachel Soon
Medical Writer
28 Feb 2018

Since the US FDA’s approval of the first cyclin-dependent kinase (CDK) inhibitor in February 2015, the molecules continue to be put to the test as part of the treatment regimen for patients with oestrogen receptor-positive metastatic breast cancers (ER+ MBC), whether as first- or second-line therapies. While overall survival data has yet to mature from clinical trials, the intermediate results appear to support the present use of CDK 4/6 in combination with endocrine therapy in delaying further onset of the disease.

Recent updates on CDK 4/6 trials were reviewed and discussed at the recent European Society for Medical Oncology (ESMO) Congress 2017 in Madrid, Spain, by Dr Alessandra Gennari, medical director of the Division of Medical Oncology of Galliera Hospital, Genoa, Italy; as well as at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting in Chicago, USA, by Dr Ingrid A. Mayer, clinical director of the Breast Cancer Research Program at Vanderbilt-Ingram Cancer Center, Nashville, USA.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 5 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Stephen Padilla, 4 days ago
Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).